News | March 01, 2025
Biocon launches GLP -1, Liraglutide, in UK
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
The PIPE offering consists of 36,190,476 units
Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score
We have big plans across our B2C and B2B businesses in India and abroad
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
USFDA inspection at Emcure Pharmaceuticals API facility
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
This will lead to the consolidation and optimization of the company's operations related to the manufacturing of ampoules and vials
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
Subscribe To Our Newsletter & Stay Updated
